MetaCap

Alterity Therapeutics Limited ADR (ATHE)

NASDAQ: ATHEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.52-0.135 (-8.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ATHE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$29.02M
EPS (TTM)
-$0.90
52-week range
1.52 – 5.89
Day range
1.52 – 1.64
Volume / Avg
20.24K / 89.63K
Beta
—

52-week range

$1.52$5.89

ATHE stock today

Shares of Alterity Therapeutics (ATHE) finished lower on Nov 20 at $1.52, a drop of 8.16% or $0.135 per share, versus the S&P 500's 3.70% decline. Trading was light, with 20.24K shares changing hands, about 23% of the average daily volume. At this level, ATHE sits near the bottom of its 52-week range of $1.52 to $5.89: 74.2% below the high, set on Jul 6, 2026 and 0.0% above the low.

ATHE is down 50.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.7%. Alterity Therapeutics has posted a net loss over the last twelve months (EPS of -$0.90), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alterity Therapeutics

Company profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David A. Stamler M.D.
Headquarters
Melbourne, VIC
Employees
11

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$13.25+771.71%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

ATHE news

All ATHE news

Alterity Therapeutics peers

Health Care sector
ATHE peer companies
CompanyPrice% ChgMarket capCompare
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs ATHE
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs ATHE
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs ATHE
NXTCNextCure Inc.6.45-4.87%$29.53Mvs ATHE
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs ATHE
SERSerina Therapeutics Inc.1.12-6.67%$29.76Mvs ATHE
EDSAEdesa Biotech Inc.2.00-8.05%$27.02Mvs ATHE
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs ATHE

Indexes, lists and sector

Alterity Therapeutics stock FAQ

What is Alterity Therapeutics's stock price today?

ATHE last traded at $1.52 as of Nov 20, 4:00 PM EST, down 8.16% on the day. Prices are delayed at least 15 minutes.

Does Alterity Therapeutics pay a dividend?

No. Alterity Therapeutics does not currently pay a regular cash dividend.

Who is Alterity Therapeutics's CEO?

Dr. David A. Stamler M.D. is the chief executive officer of Alterity Therapeutics Limited ADR, which has about 11 employees.

Has ATHE ever split its stock?

Yes. The most recent ATHE stock split was a 1-for-10 split on Jan 9, 2023, one of 2 splits on record.

What is the ATHE 52-week high?

The 52-week high for ATHE is $5.89 and the 52-week low is $1.52. The stock is currently 74.2% below its high.

Compare ATHE